Healthcare
Incannex Healthcare Limited(IXHL)
Live Price
Offline$3.83
+0.26% today
1Y Change
-42.10%
Window
Jun 25, 2025 → Jun 17, 2026
- Market Cap
- $50.00M
- Revenue Growth
- +378.7%
- EPS Growth
- -1093.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Incannex Healthcare Limited (IXHL) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $3.83 and down 42.1% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +378.7%, EPS growth of -1093.0%, a dividend yield of 0.0%. What stands out right now is revenue +378.7%, EPS -1093.0%, free cash flow +22.3% with operating margin -41819.6% and ROIC -48.9%. Valuation already assumes a fairly strong business story at price/sales 614.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IXHL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+378.7% vs +7.6% peer median
Operating Margin
Below sector median
-41819.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +378.7% and EPS is at -1093.0%, with operating margin around -41819.6%.
Benchmark Edge
IXHL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IXHL
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IXHL Max Drawdown
-94.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IXHL and SPY.
Company Overview
Incannex Healthcare Limited
NASDAQ Global Market
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
- Leadership
- Joel Bradley Latham
- IPO Date
- Mar 2, 2022
- Employees
- 9
- Street Address
- 207/11 Solent Circuit
- Mailing
- Sydney, NSW, 2153
- Region
- Sydney, NSW, AU
- Reporting Currency
- USD
- Investor Line
- 61 4 2570 3805
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.3
- Price/Sales
- 614.3
- Price/Book
- 0.7
Growth
- Revenue
- +378.7%
- EPS
- -1093.0%
- Free Cash Flow
- +22.3%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -41819.6%
- Net Margin
- -67722.1%
- ROE
- -199.1%
- ROIC
- -48.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 45.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.